Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$3.60M | -$7.73M | -$14.9M | -$16.4M | -$15.4M | -$19.8M |
| Net income | -$3.58M | -$7.71M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| EPS (diluted) | -$1.84 | -$1.89 | -$1.73 | -$1.83 | -$44.96 | -$21.58 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.32M | -$11.3M | -$13.1M | -$13.4M | -$12.3M | -$14.8M |
| Capital expenditures | — | $3.85K | — | — | — | — |
| Free cash flow | — | -$11.3M | — | — | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.64M | $39.1M | $9.63M | $13.4M | $5.79M | $8.51M |
| Total assets | $1.78M | $40.6M | $28.1M | $14.9M | $7.34M | $9.31M |
| Total liabilities | $2.02M | $4.68M | $3.43M | $2.85M | $3.39M | — |
| Shareholders' equity | -$238K | $35.9M | $24.6M | $12.1M | $3.94M | $3.15M |
| Retained earnings | -$7.96M | -$15.7M | -$30.0M | -$45.4M | -$60.4M | -$81.3M |
| Shares (wtd avg diluted) | 1.94M | 4.09M | 8.26M | 8.40M | 334K | 966K |
Every figure is extracted from Indaptus Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.